Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the challenges ahead for the European biosimilars market.
Transcript:
If I look at the market unfolding, let's say, I think one of the very important notions that needs to be reconciled is the short-term policy regarding budget management and the longer-term goal of healthcare equity and a greater quality of care because you can't forget that end goal and compromise it; you need to make sure you have thoughtful policies in place today so that you're not compromising meeting the big end goal.
I think this is essential and it has to do with a general education that competition in the pharmaceutical market is a dynamic and cyclic system, and for that, the time element is really important. It has to be seen in a bigger time frame than just the cycle of a call for tender or a purchasing bid, or this type of element.
For us, the challenge this year will be to make sure everybody in the healthcare community, from the makers to the end users, do have that time element to it. Yes there is “what's in it for me?” at every bit, but I think the time element will condition how deliverables are are actually happening or not, so this is really important.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.